Immunoprecise Stock Buy Hold or Sell Recommendation

IPA -  USA Stock  

USD 5.30  0.15  2.75%

Considering the 90-day investment horizon and your above-average risk tolerance, our recommendation regarding Immunoprecise Antibodies is 'Hold'. Macroaxis provides Immunoprecise Antibodies buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding IPA positions. The advice algorithm takes into account all of Immunoprecise Antibodies' available fundamental, technical, and predictive indicators you will find on this site.
  
Refresh
The advice is provided from Immunoprecise Antibodies' buy-and-hold perspective. Please see Immunoprecise Antibodies Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. We conduct extensive research on individual companies such as Immunoprecise and provide practical buy, sell, or hold advice based on selected investing horizon and risk tolerance towards Immunoprecise Antibodies.

Execute Immunoprecise Antibodies Buy or Sell Advice

The Immunoprecise recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Immunoprecise Antibodies. Macroaxis does not own or have any residual interests in Immunoprecise Antibodies or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Immunoprecise Antibodies' advice using the current market data and latest reported fundamentals.

Time Horizon

Risk Tolerance

Execute Advice
Sell Immunoprecise AntibodiesBuy Immunoprecise Antibodies
Hold

Volatility

Moderately volatileDetails

Hype Condition

Under hypedDetails

Current Valuation

UndervaluedDetails

Odds of Distress

Below AverageDetails

Economic Sensitivity

Almost mirrors the marketDetails

Analyst Consensus

Strong BuyDetails

Financial Strenth (F Score)

PoorDetails

Financial Leverage

InapplicableDetails

Reporting Quality (M-Score)

Unlikely ManipulatorDetails
For the selected time horizon Immunoprecise Antibodies has a Risk Adjusted Performance of 0.0765, Jensen Alpha of 0.2311, Total Risk Alpha of 0.2341, Sortino Ratio of 0.0559 and Treynor Ratio of 0.2281
We provide advice to complement the regular expert consensus on Immunoprecise Antibodies. Our dynamic recommendation engine utilizes a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time. To make sure Immunoprecise Antibodies is not overpriced, please check out all Immunoprecise Antibodies fundamentals, including its number of shares shorted, net income, book value per share, as well as the relationship between the revenue and total debt . Given that Immunoprecise Antibodies has a shares owned by institutions of 7.40 %, we strongly advise you to confirm Immunoprecise Antibodies market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your regular risk tolerance and investing horizon.

Immunoprecise Antibodies Trading Alerts and Improvement Suggestions

Immunoprecise Antibodies has very high historical volatility over the last 90 days
Immunoprecise Antibodies was previously known as IMMUNOPRECISE ANTIBODIES LTD and was traded on NASDAQ Exchange under the symbol IPATF.
The company reported the last year's revenue of 19 M. Reported Net Loss for the year was (17.1 M) with profit before taxes, overhead, and interest of 11.4 M.
Immunoprecise Antibodies has about 32.99 M in cash with (8.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.7.
Immunoprecise Antibodies has a poor financial position based on the latest SEC disclosures
Latest headline from www.digitaljournal.com: Biotech Recovery Accelerates These Companies Benefit - Digital Journal

Immunoprecise Antibodies current analysts advice

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Immunoprecise analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Immunoprecise analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Mean Price11.76
Target Median Price11.76
Target High Price11.76
Recommendation Mean2.00
Number Of Analyst Opinions1
Target Low Price11.76
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.

Immunoprecise Antibodies Returns Distribution Density

The distribution of Immunoprecise Antibodies' historical returns is an attempt to chart the future uncertainty of Immunoprecise Antibodies' future price movements. The chart of the probability distribution of Immunoprecise Antibodies stock daily returns describes the distribution of returns around its average expected value. We use Immunoprecise Antibodies price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Immunoprecise Antibodies returns is essential to provide solid investment advice for Immunoprecise Antibodies stock.
Mean Return0.24Value At Risk-7.11
Potential Upside8.54Standard Deviation4.74
 Return Density 
      Distribution 
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Immunoprecise Antibodies historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.

Immunoprecise Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Immunoprecise Antibodies is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Immunoprecise Antibodies backward and forwards among themselves. Immunoprecise Antibodies' institutional investor refers to the entity that pools money to purchase Immunoprecise Antibodies' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Ingalls Snyder LlcCommon Shares932.2 K4.8 M
Citadel Advisors LlcCall Options296.6 K1.5 M
Bank Of MontrealCommon Shares140.5 K718 K
Ikarian Capital LlcCommon Shares77.7 K399 K
Bank Of America CorpCommon Shares57.5 K295 K
Susquehanna International Group LlpPut Options36.1 K186 K
Gradient Capital Advisors LlcCommon Shares20 K103 K
Jpmorgan Chase CoCommon Shares19.9 K102 K
Geode Capital Management LlcCommon Shares17.5 K89 K
Note, although Immunoprecise Antibodies' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Immunoprecise Antibodies Greeks

Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Immunoprecise Antibodies or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Immunoprecise Antibodies stock's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Immunoprecise stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α
Alpha over DOW
0.23
β
Beta against DOW1.01
σ
Overall volatility
4.72
Ir
Information ratio 0.0488

Immunoprecise Antibodies Volatility Alert

Immunoprecise Antibodies shows above-average downside volatility for the selected time horizon. We advise investors to inspect Immunoprecise Antibodies further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Immunoprecise Antibodies future alpha. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Immunoprecise Antibodies' stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Immunoprecise Antibodies' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Immunoprecise Antibodies Implied Volatility

Immunoprecise Antibodies' implied volatility exposes the market's sentiment of Immunoprecise Antibodies stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Immunoprecise Antibodies' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Immunoprecise Antibodies stock will not fluctuate a lot when Immunoprecise Antibodies' options are near their expiration.

Immunoprecise Antibodies Fundamentals Vs Peers

Comparing Immunoprecise Antibodies' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Immunoprecise Antibodies' direct or indirect competition across all of the common fundamentals between Immunoprecise Antibodies and the related equities. This way, we can detect undervalued stocks with similar characteristics as Immunoprecise Antibodies or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Immunoprecise Antibodies' fundamental indicators could also be used in its relative valuation, which is a method of valuing Immunoprecise Antibodies by comparing valuation metrics with those of similar companies.
    
 Better Than Average     
    
 Worse Than Average Compare Immunoprecise Antibodies to competition
FundamentalsImmunoprecise AntibodiesPeer Average
Return On Equity(42.77) %(0.31) %
Return On Asset(18.66) %(0.14) %
Profit Margin(89.98) %(1.27) %
Operating Margin(78.59) %(5.51) %
Current Valuation78.03 M16.62 B
Shares Outstanding19.43 M571.82 M
Shares Owned by Insiders6.92 %10.09 %
Shares Owned by Institutions7.40 %39.21 %
Number of Shares Shorted291.31 K4.71 M
Price to Book2.02 X9.51 X
Price to Sales5.42 X11.42 X
Revenue19 M9.43 B
Gross Profit11.4 M27.38 B
EBITDA(14.06 M)3.9 B
Net Income(17.1 M)570.98 M
Cash and Equivalents32.99 M2.7 B
Cash per Share1.70 X5.01 X
Total Debt2.81 M5.32 B
Debt to Equity0.06 %48.70 %
Current Ratio5.68 X2.16 X
Book Value Per Share2.63 X1.93 K
Cash Flow from Operations(8.87 M)971.22 M
Short Ratio7.78 X4.00 X
Earnings Per Share(0.62) X3.12 X
Number of Employees7318.84 K
Beta-0.14-0.15
Market Capitalization102.98 M19.03 B
Z Score21.68.72

About Immunoprecise Antibodies Buy or Sell Advice

When is the right time to buy or sell Immunoprecise Antibodies? Buying financial instruments such as Immunoprecise Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the stock market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Although Immunoprecise Antibodies investors may find it confusing at the beginning, most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
 2019 2020 2021 2022 (projected)
Current Assets7.7 M48.86 M56.19 M60.62 M
Total Assets27.26 M66.96 M77 M64.2 M

Use Investing Ideas to Build Portfolios

In addition to having Immunoprecise Antibodies in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Restaurants Hotels Motels Thematic Idea Now

Restaurants Hotels Motels
Restaurants Hotels Motels Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Restaurants Hotels Motels theme has 61 constituents.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Restaurants Hotels Motels Theme or any other thematic opportunities.
View All  Next Launch Restaurants Hotels Motels
Please see Immunoprecise Antibodies Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note that the Immunoprecise Antibodies information on this page should be used as a complementary analysis to other Immunoprecise Antibodies' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Fund Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.

Complementary Tools for Immunoprecise Stock analysis

When running Immunoprecise Antibodies price analysis, check to measure Immunoprecise Antibodies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunoprecise Antibodies is operating at the current time. Most of Immunoprecise Antibodies' value examination focuses on studying past and present price action to predict the probability of Immunoprecise Antibodies' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immunoprecise Antibodies' price. Additionally, you may evaluate how the addition of Immunoprecise Antibodies to your portfolios can decrease your overall portfolio volatility.
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Is Immunoprecise Antibodies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunoprecise Antibodies. If investors know Immunoprecise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunoprecise Antibodies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Immunoprecise Antibodies is measured differently than its book value, which is the value of Immunoprecise that is recorded on the company's balance sheet. Investors also form their own opinion of Immunoprecise Antibodies' value that differs from its market value or its book value, called intrinsic value, which is Immunoprecise Antibodies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunoprecise Antibodies' market value can be influenced by many factors that don't directly affect Immunoprecise Antibodies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunoprecise Antibodies' value and its price as these two are different measures arrived at by different means. Investors typically determine Immunoprecise Antibodies value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunoprecise Antibodies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.